Safety of Purified Poloxamer 188 in Sickle Cell Disease: Phase I Study of a Non‐ionic Surfactant in the Management of Acute Chest Syndrome

References

• Platt O S, Brambilla D J, Rosse W F, Milner P F, Castro O, Steinberg M H, Klug P P. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639–1644
   PubMed Web of Science ®Google Scholar
• Sprinkle R H, Cole T, Smith S, Buchanan G R. Acute chest syndrome in children with sickle cell disease: a retrospective analysis of 10 hospitalized cases. Am J Pediatr Hematol/Oncol 1986; 8: 105–110
   PubMedGoogle Scholar
• Vichinsky E P, Neumayr L D, Earles A N, Williams R, Lennette E T, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci E A, National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000; 342: 1855–1865
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Williams R, Das M, Earles A N, Lewis N, Adler A, McQuitty J. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83: 3107–3112
   PubMed Web of Science ®Google Scholar
• Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Curr Opin Hematol 1998; 5: 89–92
   PubMedGoogle Scholar
• Vichinsky E. Transfusion therapy. Sickle Cell Disease. Basic Principles and Clinical Practice, S H Embury, R P Hebbel, N Mohandas, M H Steinberg. Raven Press, New York 1994; 781–794
   Google Scholar
• Olivieri N F. Clinical effectiveness of chelating therapy. Presented at Current Biochemistry to New Chelator Development Strategies. September, 21–221998. National Institutes of Health, Bethesda, MD
   Google Scholar
• Carr M E, Powers P L, Jones M R. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb Haemost 1991; 66: 565–568
   PubMed Web of Science ®Google Scholar
• Carter C, Fisher T C, Hamai H, Johnson C S, Meiselman H J, Nash G B, Stuart J. Haemorheological effects of a nonionic copolymer surfactant (Poloxamer 188). Clin Hemorheol 1992; 12: 109–120
   Google Scholar
• McKenna R, Cole E, MacLeod C, Emanuele M, Hunter R. The effects of RheothRx on platelet function and coagulation in man. Blood 1989; 74: 411
   Google Scholar
• Grover F L, Kahn R S, Heron M W, Paton B C. A nonionic surfactant and blood viscosity. Arch Surg 1973; 106: 307–310
   PubMedGoogle Scholar
• Schaer G L, Spaccavento L J, Browne K F, Krueger K A, Krichbaum D, Phelan J M, Fletcher W O, Grines C L, Edwards S, Jolly M K, Gibbons R J. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double‐blind, placebo‐controlled trial. Circulation 1996; 94: 298–307
   PubMedGoogle Scholar
• O'Keefe J H, Grines C L, DeWood M A, Schaer G L, Browne L, Magorien R D, Kalbfleisch J M, Fletcher W O, Jr, Bateman T M, Gibbons R J. Poloxamer 188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78: 747–750
   PubMed Web of Science ®Google Scholar
• Maynard C, Swenson R, Paris J A, Martin J S, Hallstrom A P, Cerqueira M D, Weaver W D. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. Am Heart J 1998; 135: 797–804
   PubMed Web of Science ®Google Scholar
• Yusuf S, for the Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. Circulation 1997; 96: 192–201
   PubMedGoogle Scholar
• Orringer E P, Casella J F, Ataga K I, Koshy M, Adams‐Graves P, Luchtman‐Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz‐Praga S, Grindel J M. Purified poloxamer 188 for treatment of acute vaso‐occlusive crisis of sickle cell disease. JAMA 2001; 286: 2099–2106
   PubMed Web of Science ®Google Scholar
• Casella J F, Wojtowicz‐Praga S, Grindel J M. A Phase III multicenter, randomized, double‐blind, placebo‐controlled study of FLOCOR (purified poloxamer 188) in patients with sickle cell disease in acute vaso‐occlusive crisis. Presented at the 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia, PA, April, 9–122000
   Google Scholar
• Casella J F, Watanabe M, Files B, Shafer F, Luchtman‐Jones L, Wun T, Emanuele M, Grindel J M. FLOCOR's efficacy and safety in pediatric sickle cell patients experiencing acute vaso‐occlusive crisis: a subgroup analysis. Blood 2000; 96: 9a
   PubMed Web of Science ®Google Scholar
• Adams‐Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edward S, Bustrack J, Emanuele M. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997; 90: 2041–2046
   PubMed Web of Science ®Google Scholar
• Luchtman‐Jones L, Files B, Ballas S K, Swerdlow P, Benjamin L, Hilliard L, Coates T, Abboud M, Wojtowicz‐Praga S, Grindel J M. Phase I study of FLOCOR in patients with acute chest syndrome of sickle cell disease. Blood 1999; 94: 25b
   Google Scholar
• Jewell R C, Khor S P, Kisor D F, LaCroix K AK, Wargin W A. Pharmacokinetics of RheothRx injection in healthy male volunteers. J Pharm Sci 1997; 86: 808–812
   PubMed Web of Science ®Google Scholar
• Vichinsky E P, Styles L A, Colangelo L H, Wright E C, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997; 89: 1787–1792
   PubMed Web of Science ®Google Scholar
• Castro O, Brambilla D J, Thorington B, Reindorf C A, Scott R B, Gillette P, Vera J C, Levy P S. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84: 643–649
   PubMed Web of Science ®Google Scholar
• Koren A, Wald I, Halevi R, Ben Ami M. Acute chest syndrome in children with sickle cell anemia. Pediatr Hematol Oncol 1990; 7: 99–107
   PubMed Web of Science ®Google Scholar
• Miller S T, Hammerschlag M R, Chirgwin K, Rao S P, Roblin P, Gelling M, Stilerman T, Schachter J, Cassell G. Role of chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 1991; 118: 30–33
   PubMed Web of Science ®Google Scholar
• Godeau B, Schaeffer A, Bachir D, Fleury‐Feith J, Galacteros F, Verra F, Escudier E, Vaillant J N, Brun‐Buisson C, Rahmouni A, Allaoui A S, Lebargy F. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome. Value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153: 1691–1696
   PubMed Web of Science ®Google Scholar
• Lowenthal E A, Wells A, Emanuel P D, Player R, Prchal J T. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol 1996; 51: 207–213
   PubMed Web of Science ®Google Scholar
• Rucknagel D L, Kalinyak K A, Gelfand M J. Rib infarcts and acute chest syndrome in sickle cell disease. Lancet 1991; 337: 831–833
   PubMed Web of Science ®Google Scholar
• Gelfand M J, Daya S A, Rucknagel D L, Kalinyak K A, Paltiel H J. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med 1993; 34: 614–618
   PubMed Web of Science ®Google Scholar
• Bhalla M, Abboud M R, McLoud T C, Shepard J A, Munden M M, Jackson S M, Beaty J R, Laver J H. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology 1993; 187: 45–49
   PubMed Web of Science ®Google Scholar
• Bernini J C, Rogers Z R, Sandler E S, Reisch J S, Quinn C T, Buchanan G R. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92: 3082–3089
   PubMed Web of Science ®Google Scholar
• Mallouh A A, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child 1998; 142: 178–182
   Google Scholar
• Emre U, Miller S T, Gutierez M, Steiner P, Rao S P, Rao M. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127: 901–904
   PubMed Web of Science ®Google Scholar
• Kress J P, Pohlman A S, Hall J B. Determination of hemoglobin saturation in patients with acute sickle chest syndrome: a comparison of arterial blood gases and pulse oximetry. Chest 1999; 115: 1316–1320
   PubMed Web of Science ®Google Scholar
• Emre U, Miller S T, Rao S P, Rao M. Alveolar‐arterial oxygen gradient in acute chest syndrome of sickle cell disease. J Pediatr 1993; 123: 272–275
   PubMed Web of Science ®Google Scholar
• Bowen E F, Crowston J G, De Ceulaer K, Serjeant G R. Peak expiratory flow rate and the acute chest syndrome in homozygous sickle cell disease. Arch Dis Child 1991; 66: 330–332
   PubMed Web of Science ®Google Scholar
• Santoli F, Zerah F, Vasile N, Bachir D, Galacteros F, Atlan G. Pulmonary function in sickle disease with or without acute chest syndrome. Eur Respir J 1998; 12: 1124–1129
   PubMed Web of Science ®Google Scholar
• Stuart M J, Setty B N. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94: 1555–1560
   PubMed Web of Science ®Google Scholar